Zukunft des Managements der MASLD („metabolic dysfunction-associated steatotic liver disease“)
- 10 October 2026
- journal article
- leitthema
- Published by Springer Nature in Die Diabetologie
- Vol. 22 (7) , 782-787
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The liver in diabetes: current state and future perspectivesDiabetologia, 2026
- Pharmacological treatment of MASHDiabetologia, 2026
- Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver diseaseThe Lancet Regional Health - Europe, 2026
- Implementing sustainable liver health in Europe: a second EASL–Lancet CommissionThe Lancet, 2026
- Blood-flow restriction resistance training improves skeletal muscle mitochondrial capacity and cardiovascular risk factors in type 2 diabetesCell Metabolism, 2026
- A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitisThe Lancet Regional Health - Europe, 2025
- Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesityJournal of Hepatology, 2024
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Journal of Hepatology, 2024
- Mitochondrial alterations in fatty liver diseasesJournal of Hepatology, 2022
- Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018)The Lancet Regional Health - Europe, 2021